Amgen, Inc. – FDA 483, May 16, 2017

Amgen Inc. in Thousand Oaks, CA, received a Form 483 with five observations related to deficiencies in drug substance manufacturing. The observations highlight issues with cross-contamination prevention, cleaning validation, product hold times, validation processes, and procedural controls. These findings indicate a need for improved quality system oversight to ensure consistent and compliant operations.